๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

In Response to: Safety and efficacy of continuous insulin infusion in noncritical care settings

โœ Scribed by Russell Vinik; Robert C. Pendleton; Robert E. Jones


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
76 KB
Volume
5
Category
Article
ISSN
1553-5592

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Safety and efficacy of continuous insuli
โœ Dawn Smiley; Mary Rhee; Limin Peng; Laurian Roediger; Patrick Mulligan; Lewis Sa ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 131 KB

## Abstract ## BACKGROUND: Continuous insulin infusion (CII) to manage hyperglycemia is the accepted standard of care in the intensive care unit (ICU); however, the safety and efficacy of CII in the nonโ€ICU setting has not been determined. ## RESEARCH DESIGN AND METHODS: This is a retrospective

Efficacy and safety of continuous infusi
โœ Mรฉnart, Christophe; Petit, Pierre Yves; Attali, Olivier; Massignon, Denis; Decha ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 180 KB

We report here five surgeries successfully performed with a continuous infusion of Mononineเฎพ (Armour Pharmaceutical Company, Kankakee, IL) in three hemophilic B patients. Before surgery the patients received a bolus dose of 40 to 100 U/kg according to the type of surgery. This injection was followed

A comparison study of continuous insulin
โœ Christopher A. Newton; Dawn Smiley; Bruce W. Bode; Abbas E. Kitabchi; Paul C. Da ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 282 KB

To compare the safety and efficacy of continuous insulin infusion (CII) via a computer-guided and a standard paper form protocol in a medical intensive care unit (ICU). ## METHODS: Multicenter randomized trial of 153 ICU patients randomized to CII using the Glucommander (n ยผ 77) or a standard pap

Efficacy and safety of imatinib in patie
โœ Susan Branford; Timothy Hughes; Alvin Milner; Rachel Koelmeyer; Anthony Schwarer ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 201 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. Interferonโ€alpha (IFNโ€ฮฑ) confers a survival advantage for the minority of patients with chronic myeloid leukemia (CML) who achieve a complete cytogenetic response. The question of whether IFNโ€ฮฑโ€responsive patients can experience further improvements with imatinib has not